Discovery of a Novel Cabazitaxel Nanoparticle-Drug Conjugate (CRLX522) with Improved Pharmacokinetic Properties and Anticancer Effects Using a β-Cyclodextrin-PEG Copolymer Based Delivery Platform.
第一作者:
Chester A,Metcalf
第一单位:
Novartis Institutes for BioMedical Research Inc. , 181 Massachusetts Avenue , Cambridge , Massachusetts 02139 , United States.
作者:
主题词
动物(Animals);抗肿瘤药(Antineoplastic Agents);药物载体(Drug Carriers);药物设计(Drug Design);男(雄)性(Male);黑色素瘤, 实验性(Melanoma, Experimental);小鼠(Mice);纳米粒子(Nanoparticles);聚乙烯二醇类(Polyethylene Glycols);紫杉烷类(Taxoids);组织分布(Tissue Distribution);β环糊精类(beta-Cyclodextrins)
DOI
10.1021/acs.jmedchem.9b00892
PMID
31593466
发布时间
2020-06-15
- 浏览0

Journal of medicinal chemistry
9541-9559页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文